Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBT: 2021-2024

Historic EBT for ARS Pharmaceuticals (SPRY) over the last 4 years, with Dec 2024 value amounting to $8.3 million.

  • ARS Pharmaceuticals' EBT fell 144.58% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 50.04%. This contributed to the annual value of $8.3 million for FY2024, which is 115.24% up from last year.
  • Per ARS Pharmaceuticals' latest filing, its EBT stood at $8.3 million for FY2024, which was up 115.24% from -$54.4 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' EBT peaked at $8.3 million during FY2024, and registered a low of -$54.4 million during FY2023.
  • Over the past 3 years, ARS Pharmaceuticals' median EBT value was -$35.5 million (recorded in 2022), while the average stood at -$27.2 million.
  • Its EBT has fluctuated over the past 5 years, first plummeted by 82.56% in 2022, then skyrocketed by 115.24% in 2024.
  • Yearly analysis of 4 years shows ARS Pharmaceuticals' EBT stood at -$19.5 million in 2021, then plummeted by 82.56% to -$35.5 million in 2022, then plummeted by 53.07% to -$54.4 million in 2023, then soared by 115.24% to $8.3 million in 2024.